硼替佐米对一名经过大量预处理的难治性T细胞淋巴母细胞淋巴瘤患者的治疗。

Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.

作者信息

Mai Wenyuan, Meng Haitao, Jin Jie, Wang Lei

机构信息

Department of Hematology, the First Affiliated Hospital of ZheJiang University, HangZhou, ZheJiang, China.

出版信息

Eur J Haematol. 2006 Nov;77(5):445-7. doi: 10.1111/j.0902-4441.2006.t01-1-EJH2889.x. Epub 2006 Aug 23.

DOI:10.1111/j.0902-4441.2006.t01-1-EJH2889.x

PMID:16930138

Abstract

T-cell lymphoblastic lymphomas are highly aggressive non-Hodgkin's lymphoma (NHL) and account for approximately 3% of all adult NHL histologies, with poor prognosis. We describe a 38-year-old patient with T-cell lymphoblastic lymphoma, who responds to bortezomib and doxorubincin combination, following a failure of conventional chemotherapy. Two months after treatment, the patient showed near complete remission of the lymphadenopathy. These data suggest a possible synergistic effect with bortezomib in combination with doxorubincin and dexamethasone. To our knowledge, this is the first case of T-cell lymphoblastic lymphoma treated with bortezomib.

摘要

T细胞淋巴母细胞淋巴瘤是侵袭性很强的非霍奇金淋巴瘤（NHL），约占所有成人NHL组织学类型的3%，预后较差。我们描述了一名38岁的T细胞淋巴母细胞淋巴瘤患者，在传统化疗失败后，对硼替佐米与阿霉素联合治疗有反应。治疗两个月后，患者的淋巴结病几乎完全缓解。这些数据表明硼替佐米与阿霉素和地塞米松联合使用可能具有协同作用。据我们所知，这是首例用硼替佐米治疗的T细胞淋巴母细胞淋巴瘤病例。